Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_assertion type Assertion NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_head.
- NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_assertion description "[Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_provenance.
- NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_assertion evidence source_evidence_literature NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_provenance.
- NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_assertion SIO_000772 19855965 NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_provenance.
- NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_assertion wasDerivedFrom befree-20150227 NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_provenance.
- NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_assertion wasGeneratedBy ECO_0000203 NP978704.RAek6jwQnd5taEnga2ZMFaPgQRJf2IwrgNCelxItui6DE130_provenance.